Physician profile
John H Won
NPI 1477630440
$8,981.70
in general payments reported to CMS, 2019-2025
18 companies · $4,669 in 2025
The $4,669 reported for 2025 was more than what 90% of Urology providers received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $615 · 2020: $644 · 2021: $553 · 2022: $355 · 2023: $1,229 · 2024: $917 · 2025: $4,669.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Debt Forgiveness: $4,164 · Food and Beverage: $2,165 · Education: $485.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Debt Forgiveness | $4,164.30 |
| Food and Beverage | $2,165.21 |
| Education | $484.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Olympus America INC. | $4,164.30 | 2025 | |
| Astellas Pharma US INC | $1,017.04 | 2019-2024 | Xtandi, Myrbetriq, Veozah |
| Sumitomo Pharma America, INC. | $972.71 | 2023-2025 | Orgovyx, Gemtesa |
| Janssen Biotech, INC. | $372.81 | 2022-2025 | Erleada, Carvykti, Rybrevant |
| Teleflex LLC | $369.00 | 2021-2025 | Urolift |
| Pfizer INC. | $355.93 | 2019-2025 | |
| Neotract INC. | $320.19 | 2020 | |
| Myovant Sciences INC. | $236.20 | 2021-2022 | |
| Boston Scientific Corporation | $225.67 | 2019-2024 | Rezum Generator, Spaceoar Vue System - 10ml |
| Celltrion, INC. | $177.89 | 2019-2020 | |
| Ethicon US, LLC | $135.66 | 2023 | Echelon Flex, Stratafix, Surgicel Nu-Knit |
| Urogen Pharma, INC. | $117.89 | 2024-2025 | |
| Amarin Pharma, INC. | $117.76 | 2020 | |
| Urovant Sciences INC | $110.21 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $103.39 | 2023-2024 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Insmed, INC. | $81.68 | 2019 | |
| Telix Pharmaceuticals | $75.40 | 2024 | Illuccix |
| Progenics Pharmaceuticals, INC. | $27.97 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Won listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.